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This paper reports the development, characterization and in vitro dissolution behavior of sulfasalazine 
suspensions for treatment of chronic intestinal inflammatory diseases. Three formulations were developed, 
from powdered sulfasalazine obtained from different suppliers. The sulfasalazine was characterized 
regarding concentration, Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning 
Calorimetry (DSC), X-Ray Diffraction (XRD), particle size distribution, polydispersion and solubility. 
The suspensions were developed and characterized regarding pH, viscosity, density, particle size, 
sedimentation volume, concentration and dissolution. The pH values were slightly acidic. The method of 
preparing the suspensions reduced the particle sizes and made the size distribution more homogeneous. 
The dissolution studies showed that the sulfasalazine suspensions had low solubility in acidic media, 
but dissolve quickly, reaching levels of 85%, in neutral media or media containing 0.5% of surfactants 
such as polysorbate 80. Besides this, the sulfasalazine suspensions were classified as having immediate 
dissolution because they reached dissolution levels near 100% in 20 minutes.
Uniterms: Sulfasalazine/suspensions/dissolution. Chronic intestinal inflammatory diseases/treatment.
O trabalho reporta o desenvolvimento, caracterização e estudo in vitro de dissolução de suspensões de 
sulfassalazina para uso em doenças inflamatórias crônicas intestinais. Desenvolveram-se três formulações 
baseadas em fornecedores diferentes de pó de sulfassalazina. A sulfassalazina foi caracterizada quanto a 
Teor, Infravermelho por Transformada de Fourier (FTIR), Calorimetria Diferencial de Varredura (DSC), 
Difração de Raios-X (XRD), distribuição de tamanho das partículas, índice de polidispersão e solubilidade. 
A suspensão foi desenvolvida e caracterizada quanto a pH, viscosidade, densidade, tamanho de partícula, 
volume de sedimentação, teor e estudo de dissolução. Os valores de pH determinados foram levemente 
ácidos. O método de preparo das suspensões reduziu o tamanho das partículas e tornou a distribuição de 
tamanho mais homogênea. Os estudos de dissolução mostraram que a suspensão de sulfassalazina tem 
problemas de solubilidade em meios de caráter ácido, entretanto, sofre dissolução rápida acima de 85% 
em meios neutros ou contendo 0,5% de tensoativos como Polissobato 80. Além disso, as suspensões 
de sulfassalazina foram classificadas como formulações de dissolução imediata porque a partir de 20 
minutos sofrem dissolução em torno de 100%.
Unitermos: Sulfassalazina/suspensões/dissolução. Doenças inflamatórias crônicas intestinais/tratamento.
INTRODUCTION
Sulfasalazine (SSZ) is widely used to treat ulcerative 
colitis and Crohn’s disease. Ulcerative colitis is caused by 
inflammation of the large intestine, colon and/or rectum, 
while Crohn’s disease causes chronic inflammation, mainly 
in the lower part of the small intestine. SSZ is also used 
to treat rheumatoid arthritis and ankylosing spondylitis, 
which are the main rheumatic and autoimmune diseases 
in the world (Trinches et al., 2004; Genc et al., 2007).
SSZ is formed by the combination of 5-aminosalicylic 
acid (5-ASA) with sulfapyridine (SP) through an azo 
bond. 5-ASA also has antiinflammatory action. When 
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administered orally, 30% of the SSZ is absorbed in the 
upper part of the gastrointestinal tract and the remainder 
passes to the colon, where the azo bond is broken down by 
the action of bacterial azoreductase enzymes, releasing the 
5-ASA to act in the colon. The SP is totally absorbed and 
metabolized to N-acetyl sulfapyridine by hepatic enzymes 
(Kumagai et al., 2004). Both SSZ and SP have a variety of 
actions, such as immunomodulation, antibacterial activity 
and inhibition of folate-dependent enzymes (Kumagai et 
al., 2004).
According to the biopharmaceutical classification, 
SSZ is a class IV drug (Clarysse et al., 2011), insoluble in 
water and with low permeability. SSZ has acidic character 
due to three different groups – carboxyl, sulfonamide and 
phenolic hydroxyl – making it soluble in alkaline media 
and insoluble in acidic media. Trinches et al. (2004) 
showed that the bioavailability of SSZ is the same if 
administered in tablet or suspension form. However, in 
many countries, like Brazil, the drug is not available in 
suspension form, even though elderly and very young 
patients have trouble swallowing tablets. Grinding tablets 
into powder and addition to a liquid carrier can leave 
particles capable of clogging the catheters of bedridden 
patients receiving medicines by this route. Therefore, 
SSZ in suspension is the best method of administration 
in newborns, young children, and the elderly. Besides 
more flexible administration, the dosage of the liquid 
formulation can be adjusted more easily (Trinches et al., 
2004).
The objective of this study was the preparation, 
physical and chemical characterization and assessment of 
the dissolution profile in vitro of oral suspensions of SSZ 
250 mg/5 mL. The dissolution data of the suspension and 
the reference tablet (Azulfin®) were compared to evaluate 
the advantages of the liquid suspension in relation to the 
solid form.
MATERIAL AND METHODS
Material
The SSZ used as reference was obtained from 
Sigma (Fluka, lot 1450407, 10 g, concentration 98.3%). 
To prepare the formulations, sulfasalazine (SSZ) was 
acquired from three suppliers: SSZ-P of the KX (China), 
SSZ-D of the KZC (China), and SSZ-H of the SH (China). 
Sodium hydroxide, glacial acetic acid, acetic acid, 
phosphoric acid, monobasic potassium phosphate, sodium 
chloride and polysorbate 80 (Tween®), all PA grade, 
were obtained from Vetec (Brazil). Methanol, ethanol, 
acetonitrile, HPLC grade, were obtained from Tédia Brazil 
(Brazil). Sodium cyclamate, sodium benzoate and sodium 
carboxymethylcellulose were acquired from Pharma 
Special (Brazil). Orange essential oil was purchased from 
Dierberger (Brazil).
Characterization of the SSZ samples
The method to determine the sulfasalazine content 
was that described in the United States Pharmacopoeia 
(34th edition). This method consists of spectrophotometry 
of the sample dissolved in a sodium hydroxide 0.1N 
solution. The standard used was that obtained from 
Sigma (concentration ≥ 98%). A 150 mg sample of SSZ 
was weighed and transferred to a 100 mL amber round 
bottom beaker. The sodium hydroxide 0.1 N solution 
was added to the beaker to dissolve the SSZ. An aliquot 
of 1 mL was then transferred to a 200 mL round-bottom 
beaker containing 4 mL of the acetic acid 0.1N solution 
and the volume was completed with water. From this 
solution a 5 mL aliquot was withdrawn and the volume 
was completed with water to 10 mL. The sample was read 
at 359 nm to obtain an absorbance of 0.5. This procedure 
was carried out in triplicate.
Tablets of SSZ in potassium bromate (KBr) were 
prepared at 1% (w/w) with the standard SSZ and the 
three samples (SSZ-P, SSZ-D and SSZ-H). The spectra 
were generated by a Shimadzu Prestige 21 infrared 
spectrophotometer (Japan) in a wavelength range of 400 
to 3800 cm-1.
The X-ray diffractograms of the samples were 
obtained with a Rigaku Miniflex X-ray diffractometer 
(Japan), operating at 40.0 kV and 30.0 mA, with 2θ 
diffraction angles from 2 to 60º at room temperature 
(28±2 ºC), with Cu-Kθ radiation (λ=1.542 Angstroms) 
and scanning speed of 0.05º/s.
The DSC curves of the samples were obtained with 
a Shimadzu DSC 60 apparatus (Japan), under a dynamic 
nitrogen atmosphere (50 mL/min) and heating rate of 
15 ºC/min, in a temperature range from 35 to 500 ºC, 
in partially closed aluminum crucibles. The mass of the 
samples was 3 mg. The calorimeter was calibrated using 
metallic indium and zinc standards. 
The particle size distribution and polydispersity 
were measured with a Malvern Mastersizer 2000/2000E 
particle size analyzer(United Kingdom) using the Hydro 
2000 SM module for liquid samples. Since the best 
dispersant medium for reading the size of particles in 
suspension is a medium in which the drug is insoluble, 
we used water as the dispersant. This device uses laser 
diffraction and the particle diameter was obtained when 
the light passes through the suspension containing the 
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particles and is diffracted to a determined angle, to obtain 
the distribution. Average particle size was expressed as 
the volume mean diameter (D4.3) and polydispersity was 
given by span index. The span index can be calculated by 
the following equation:
Span Index = (D0.9 - D0.1)/D0.5 
where D0.9 is a diameter when 90% of the volume 
distribution is below this value; D0.1 is a diameter when 
10% of the volume distribution is below this value, and 
D0.5 is the diameter where 50% of the distribution is above 
and 50% is below. Span is a useful statistical parameter 
to assess the quality of a particle size distribution, which 
can be monodispersed or polydispersed (Skoog; Holler; 
Crouch, 2007).
Production and characterization of the SSZ 
suspension
The oral suspension of SSZ was produced using raw 
material from the three suppliers identified earlier: SSZ-P, 
SSZ-D and SSZ-H. The sulfasalazine suspensions were 
produced at a concentration of 50 mg/mL according to 
Figure 1. The formulations are described in Table I.
The suspensions’ density was determined using 
a 25-mL pycnometer. The pH was determined using a 
Mettler Toledo potentiometer previously calibrated with 
4.0 and 7.0 buffers. All the readings were taken at room 
temperature (25±2 °C).
The sedimentation rates were measured to assess 
the degree of redispersion of the suspension. The samples 
were transferred to 100 mL test tubes, considering the 
initial height (H0) to be 100. The height of the sediment 
0.3% sodium
carboxymethylcellulose in
water (B)
Solution of sodium benzoate
and sodium cyclamate in
water (25 °C)    (A)
Mix A and B
Add carrier (A+B)
250 mg SSZ/5 mL
Incorporate SSZ and
homogenize
Homogenize polysorbate
with orange essential oil
Homogenize for 1 hour
FIGURE 1 - Flow chart for preparation of the SSZ suspensions.
TABLE I - Sulfasalazine suspension formulations
Formulation Quantity (g)
Sulfasalazine 5.0
Sodium cyclamate 0.01
Sodium benzoate 0.5
Sodium carboxymethylcellulose 0.3
Polysorbate 80 0.5
Orange essential oil 0.2
Water (sufficient quantity for) 100 mL
(Ht) was measured from 6 to 192 hours. The Ht/H0 ratio 
was used to calculate the sedimentation rate (Prista; Alves; 
Morgado, 2008).
The particle size distribution and Span of the 
suspensions were measured in a Malvern Mastersizer 
particle size analyzer (2000/2000E, UK) using water as 
the diluent medium. Average particle size was expressed 
as the volume mean diameter (D4.3) and polydispersity was 
given by span index. The span index can be calculated by 
the following equation:
Span Index = (D0.9 - D0.1)/D0.5 
where D0.9 is a diameter when 90% of the volume 
distribution is below this value; D0.1 is a diameter when 
10% of the volume distribution is below this value, and 
D0.5 is the diameter where 50% of the distribution is above 
and 50% is below. Span is a useful statistical parameter to 
assess the quality of a particle size distribution.
The zeta potential of the samples was determined 
employing a Malvern Zetasizer (UK). 0.3 ml of the 
suspension was added into a volumetric flask with 
capacity of 10 mL. The volume was completed with 
ultrapure water. The samples was gently homogenized. 
The refractive index and the absorbance at 766 nm were 
measured for each sample and the data recorded on the 
equipment’s software. The measurements were performed 
in microelectrophoretic cell. The samples were gently 
added to the cells to avoid the formation of bubbles. Six 
readings for each sample were performed. Results were 
expressed as mean and standard deviation.
The viscosity of the suspensions was determined 
in a Brookfield viscometer (LVT) using a needle 2 and 
velocity of 30 rpm. Six determinations for each sample 
were performed at room temperature (28 oC).
The SSZ concentration was determined by high-
performance liquid chromatography (HPLC). The 
experimental conditions were those suggested by Costa 
et al. (2012). An aliquot of the suspension was placed in a 
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round bottom beaker and dissolved with acetonitrile and 
water (1:1). After dissolution, the solution was filtered 
through a Millex® membrane (0.45 µm) before analysis.
Solubility and dissolution study
Solubility is one of the most important parameters 
in pre-formulation studies (Milani-Zakeri et al., 2009; 
Clarysse et al., 2011). It was determined by adding an 
excess of SSZ in 50 mL of a dissolution medium. The 
solubility was tested in the following dissolution media: 
gastric juice (HCl 0.1 N pH 1.2), phosphate buffer pH 
5.8 (USP, 2011a), phosphate buffer pH 5.8 with 0.5% 
polysorbate 80, phosphate buffer pH 6.8 (USP, 2011a), and 
phosphate buffer pH 7.4 (USP, 2011a). The SSZ samples 
were placed in a magnetic stirrer operating at 100 rpm, at 
room temperature (25 °C ± 2 °C) for 24 h. The samples 
were centrifuged for 120 min at 4000 rpm for separation of 
the supernatant. The process was performed in triplicate. 
The SSZ concentration in the supernatant was determined 
by the spectrophotometric method described by Costa et 
al. (2012). The SSZ was dissolved in NaOH 0.1 M, diluted 
to obtain the analytic curve in the range from 2 to 12 μg/
mL. The absorbances of the solutions in aqueous and acid 
media were measured at 359 and 456nm, respectively. The 
linearity, selectivity, precision, accuracy and robustness 
were evaluated according the criteria described by Costa 
et al. (2012).
The solubility values of the SSZ in the dissolution 
media were used to establish the sink conditions. In the 
dissolution testing was used a dissolution equipment DTR6 
(Erweka). The samples were weighed and transferred 
to vessels containing 900 mL of dissolution medium. 
Due to the specific activity of SSZ in the colon and the 
physiological characteristics of the gastrointestinal system, 
we selected five media: HCl 0.1 N pH 1.2; phosphate 
buffer pH 5.8, phosphate buffer pH 5.8 with 0.5% 
polysorbate 80; phosphate buffer pH 6.8; and phosphate 
buffer pH 7.4. The dissolution tests were performed using 
USP apparatus 2 (Hanson, Gray, 2004). Rotations of 25 
and 50 rpm were tested in the dissolution testing of the 
suspensions (Siewert et al., 2003; Hanson, Gray, 2004). 
The temperature was maintained at 37±0.5 oC. Dissolution 
equipment DTR6 (Erweka) was used in the dissolution 
assays. 10 mL were collected at pre-established times. 
After sampling and filtration, the samples were diluted 
in each medium. The SSZ concentration was measured 
using the spectrophotometric method described by 
Costa et al. (2012). The method was selective, linear of 
2 to 12 µg/mL (R=0.999), precise (DPR=2.7%), accurate 
(99.7±1.3%) and robust according to Costa et al. (2012). 
The percentage of dissolved SSZ was calculated according 
to the total quantity of SSZ suspension added in the basin. 
The dissolution profile was obtained from the percentage 
of SSZ dissolved as a function of time.
The Azulfin® tablet presents gastro-resistant 
coating. Thus, the dissolution testing was measured in 
two stages (USP, 2011b). The tablets were transferred to 
900 mL of gastric juice (HCl 0.1 N, pH 1.2), temperature 
of 37 ± 0.5 °C, and stirring by paddle (Apparatus 2) at 
rotation speed of 100 rpm for 2 hours. In the second stage, 
the tablets were added to 900 mL of phosphate buffered 
saline, pH 7.4, temperature of 37±0.5 oC, and stirring by 
paddle at rotation speed of 100 rpm for 2 hours.
The dissolution data of the oral liquid suspension 
and tablet were compared to evaluate the advantages of 
the liquid in relation to the solid form.
The Graph Pad Prism software, version 5.04 (1992-
2010 Graph Pad Software, Inc.) was used to evaluate 
significant differences of the dissolved percentages 
between the SSZ-D, SSZ-H and SSZ-P formulations 
in each dissolution medium evaluated. The dissolution 
profiles were compared using two-way ANOVA, whereby 
the percentage dissolved was the dependent variable and 
time interval was the repeated factor. A p-value lower than 
0.05 was considered statistically significant.
RESULTS AND DISCUSSION
The mean concentrations and relative standard 
deviations (RSD) of the samples SSZ-D, SSZ-H and 
SSZ-P were 99.7±0.41, 100.3±0.38 and 99.2±0.65%, 
respectively. These SSZ concentrations are within the 
range of acceptable limits of 98.5 to 100.5% recommended 
by the USP 34th edition (2011b). The RSD values were 
also satisfactory, below the level of 2% recommended by 
the same source.
The FTIR spectra of the samples and the standard 
substance (Table II) were similar, with presence of the 
bands mentioned in the literature (Moffat, Osselton, 
Widdop, 2004). There was a pronounced band at 
768 cm-1, referring to the vibration of the C–H bond of 
the aromatic ring, bands at 1082 cm-1, 1128 cm-1 and 
1173 cm-1, referring to C–O deformations characteristic of 
stretching of the C=O and C=N bonds, and deformation of 
the N-H bond. In the region between 3400 and 3450 cm-1, 
there were bands characteristic of stretching of the 
oxygen-hydrogen bond referring to the phenolic group 
and carboxylic acid group.
The XRD results for the samples SSZ-H, SSZ-P 
and SSZ-D showed that the substances have XRD 
profile similar to that of the standard substance (Sigma) 
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TABLE II - FTIR results of samples SSZ-P, SSZ-D, SSZ-H and 
Sigma standard
Standard
λmax (cm-1)
SSZ-D SSZ-H SSZ-P
768 767 766 767
1082 1081 1082 1083
1128 1128 1128 1126
1173 1171 1172 1172
1637 1635 1636 1637
1676 1676 1675 1677
TABLE III - Solubility values (mg/mL) of the samples of SSZ from suppliers D, H and P measured by UV/Vis spectrophotometry 
at 25 °C (±2 °C)
Medium λ(nm) D H P
HCl 0.1 N pH 1.2 359 0.018±0.002 0.021±0.002 0.023±0.003
Phosphate buffer (pH 5.8) 359 0.299±0.045 0.154±0.008 0.367±0.029
Phosphate buffer (pH 5.8) with 0.5% polysorbate 80 359 0.739±0.059 0.757±0.044 0.679±0.031
Enteric juice (pH 6.8) 359 2.759±0.206 2.080±0.050 1.509±0.425
Phosphate buffer saline (pH 7.4) 456 6.890±0.059 4.030±0.090 5.306±0.649
Mean ± Standard Deviation of n=6 determinations
FIGURE 2 - Diffractograms of SSZ: Sigma standard, sample P, 
sample H and sample D.
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FIGURE 3 - DSC curves of SSZ: Sigma standard, sample P, 
sample H and sample D.
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(Figure 2), with well-defined crystalline structure and 
characteristic signals at 11.9°, 15.1°, 24.1° and 27.6°. 
However, a variation can be seen in the intensity of the 
peaks for the substances obtained from suppliers H and 
D at 24.1°. The alteration in the intensity of the peaks can 
be related to the organizational structure of the crystals.
Figure 3 shows the DSC curves obtained with the 
three samples and the standard SSZ. The endothermic 
peak refers to the melting of the samples, which occurred 
at 259.88 °C for the Sigma standard and 259.34 °C, 
260.17 °C and 259.56 °C for the samples from suppliers D, 
H and P, respectively. At this stage, the sample passes from 
a rigid state to a more flexible structure, characteristic of 
an endothermic event, and its mobility allows alleviating 
the strain. No other event was observed at a different 
temperature in the DSC curves of the samples from the 
three suppliers, indicating the existence of sulfasalazine 
without polymorphism. The next event is a peak resulting 
from the sample’s decomposition. 
The results show that the solubility of SSZ increases 
with increasing pH of the medium due to its acidic 
character (Table III). The solubility values in hydrochloric 
acid 0.1 N were low. The use of the surfactant increased the 
SSZ’s solubility. There were also differences in solubility 
of samples D, H and P. This difference shows that the lots 
from the three suppliers have different characteristics. As 
the pH of the media increases, becoming more basic, the 
solubility increases due to the acidic character of SSZ. 
The increase of pH causes a shift of the equilibrium point, 
increasing the ionized form of SSZ, as indicated by the 
strong yellow color at pH 7.4. In this case, a bathochromic 
shift occurs in the wavelength of maximum absorption, 
from 359 to 456 nm (Table III).
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Table IV shows the particle size distribution of 
samples D, P and H and the SSZ suspensions. The three 
SSZ samples all had large particles with high span values, 
indicating wide size distribution, classifying them as 
polydispersed. The sizes of the particles in suspension 
were smaller and the size distribution was narrower, as 
indicated by the span values. The suspension produced 
with sample H had the smallest average particle size among 
the suspensions. All the samples presented negative zeta 
potential values. The negative charge can help stabilize the 
suspension due to the repulsive force between the particles. 
This negative charge of the particles is due to the ionization 
of the carboxylic acid group of the SSZ molecule.
The density, pH and viscosity values of the 
suspensions SSZ-D, SSZ-H and SSZ-P are shown in 
Table V. The suspensions’ density was similar to that of 
water, while the pH was slightly acidic due to the acidic 
character of SSZ. The viscosity was similar among the 
formulations.
We monitored the sedimentation volume for 192 
hours to assess the flocculation degree. After 12 hours 
the three suspensions presented sedimentation volume 
values (F) near 1, while after 192 hours the suspensions 
presented values below 0.35 and slow sedimentation 
speeds, classifying them as deflocculated. However, when 
shaken for 1 minute they presented good redispersion, 
without caking.
According to the RSD values shown in Table VI, 
in all cases after homogenization for 1 minute, the 
suspensions presented RSD values lower than 2.0%, below 
the acceptance criterion for homogeneity (USP,, 2011b). 
Considering a variation in the sulfasalazinecontent of 
± 10%, the limit should be between 45.0 and 55.0 mg/mL. 
All the suspensions remained within this interval.
TABLE IV - Parameters considered in the characterization of the raw materials and the 250 mg/5 mL sulfasalazine suspension
Distribution
Particle size of raw materials (µm) Particle size of the suspension (µm)
D H P SD SH SP
D50 4.94 6.68 4.67 2.92 2.30 3.97
D10 1.13 1.28 1.12 0.96 0.94 1.41
D90 33.05 89.51 69.03 12.27 6.43 11.74
Span 32.82 89.32 14.54 3.87 2.38 2.60
Zeta potential* -39.15±2.25 -47.83±1.04 -46.03±2.86
Mean of n=3 determinations. *Mean and standard deviation of n=3 determinations
TABLE V - Values of pH, density and viscosity of SSZ 
250 mg/5 mL from three suppliers (D, H and P)
Parameters SSZ-D SSZ-H SSZ-P
Density (g/mL) 1.0205 1.0185 1.0218
pH 5.25 5.32 5.20
Viscosity (cPs) 70 70 75
Mean of n=3 determinations
TABLE VI - SSZ concentrations found in suspensions D, H and P by the spectrophotometric method
Sample Suspension
Morning (9:00 h) Afternoon (15:00 h) Final Mean 
(mg/mL)mg/mL Mean RSD (%) mg/mL Mean RSD (%)
D
Top 48.34
48.3 0.52
46.54
46.7 0.52 47.5 Middle 48.01 46.54
Bottom 48.50 46.96
H
Top 49.30
48.8 1.74
47.89
48.3 0.91 48.5Middle 49.22 48.22
Bottom 47.79 48.76
P
Top 52.60
53.5 1.63
53.39
53.1 0.46 53.3Middle 53.64 53.09
Bottom 54.34 52.90
RSD- Relative Standard Deviation
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The sink conditions were not satisfied in the simulated 
gastric juice (HCl 0.1 N, pH 1.2), because SSZ has low 
solubility in acidic media. Thus, others media were chosen 
to attain sink conditions. Figure 4 shows the dissolution 
profiles of the suspensions in the acidic medium. In this 
medium, the SSZ particles remained virtually insoluble. 
The samples were collected during a period of 120 minutes 
and the quantity of dissolved SSZ was measured. Rotation 
of 25 rpm (Figure 4A) was not sufficient for the study due 
to the high standard deviations caused by the insolubility 
of the drug in the medium. This rotation speed was not 
able to homogenize the suspension of SSZ particles in the 
receiving medium. On the other hand, the speed of 50 rpm 
(Figure 4B) was adequate for the dissolution study in the 
acidic medium, in which 10% of the drug was dissolved 
after 120 min. However, the suspension produced with 
sample SSZ-P did not reach 10% dissolution as it did for 
the other samples (SSZ-D and SSZ-H). Besides this, sink 
conditions were not attained in the dissolution study due to 
the low solubility of the drug in acidic media, which causes 
saturation of the medium and hampers determination of the 
dissolution profile (Hanson; Gray, 2004).
The dissolution profiles of the suspensions in 
phosphate buffer are shown in Figures 5, 6, 7 and 8.
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FIGURE 4 - Dissolution profiles of suspensions of SSZ (250 
mg/5 mL) in HCl 0.1 N pH 1.2, at 25 rpm (A) and 50 rpm (B). 
Mean and standard deviation of n=6 determinations.
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FIGURE 5 - Dissolution profiles of suspensions of SSZ (250 
mg/5 mL) mL in phosphate buffer saline pH 5.8, at rotations 
of 25 rpm (A) and 50 rpm (B). Mean and standard deviation of 
n=6 determinations.
The results of the two-way Anova for the phosphate 
buffer pH 5.8 medium at 25 rpm (Figure 5A) show there was 
a significant difference in the dissolved percentage (P<0.05) 
between formulations D and H at each time interval, with 
the exception of 90 minutes, and between D and P for all 
dissolution times. The results also show that formulation 
D had a different dissolution profile than suspensions P 
and H. Between formulations H and P, in phosphate buffer 
pH 5.8 and velocity of 25 rpm, there was no significant 
difference (P > 0.05) between the profiles. After 15 minutes, 
formulation P presented a dissolved percentage of 100.14% 
while the figure for formulation H was 96.53% (Figure 
5A). In the phosphate buffer pH 5.8 dissolution medium at 
rotation of 50 rpm, no significant differences (P > 0.05) were 
observed for any of the formulations. At a rotation speed 
50 rpm (Figure 5B), the drug dissolved completely after 
15 minutes for formulations P (101.88%) and H (99.13%). 
However, the suspension produced with sample SSZ-D 
showed dissolution of 90.16% with high standard deviations 
(Figure 5B).
The dissolution behavior of formulations D, H 
and P in the phosphate buffer pH 5.8 medium with 0.5% 
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polysorbate 80 was considerably better than in phosphate 
buffer pH 5.8 alone, since the surfactant improved the 
average solubility of the drug in this medium, from 
273 μg/mL to 725 μg/mL (2.6 times). As can be seen in 
Figure 6, the dissolution curves for the suspensions using 
rotation of 25 rpm were similar. Figure 6A shows a large 
and significant difference between suspensions D and H at 
the first time (P < 0.0001) and between D and P for times 
of 1 and 10 minutes (P < 0.05). After these initial intervals, 
the dissolution of the suspensions was similar, reaching a 
plateau after 15 minutes. The significant difference at the 
start of dissolution between formulations D versus P and D 
versus H can be related to the low rotation speed, because 
the RSD obtained for formulation D at the first time was 
above 10%. The dissolution profiles of the suspensions 
at 50 rpm (Figure 6B) were similar, with no significant 
differences (P>0.05). The sink condition was attained at 
6.5 times bellow the saturation concentration of the drug.
In the phosphate buffer pH 6.8 medium (Figure 7), 
all the suspensions reached dissolution levels above 
85% at rotations of 25 and 50 rpm in 15 minutes. These 
suspensions can therefore be classified as immediate 
release formulations (ANVISA, 2010; Storpirtis et 
al., 2009; Manadas, Pina, Veiga, 2002). At 25 rpm 
(Figure 7A) there were significant differences (P < 0.05) 
between formulation D and H and between D and P for 
the first dissolution times. However, as of 10 minutes the 
dissolution profiles did not present significant differences. 
At 50 rpm the dissolution profiles of the suspensions did 
not differ significantly (Figure 7B).
Figures 8A and B show the dissolution profiles of the 
suspensions in pH 7.4 buffer. In this medium, there was 
no significant difference (P>0.05) between the dissolution 
profiles of the formulations at the two rotation speeds used. 
In all cases, 100% dissolution was achieved in 15 minutes, 
characteristic of immediate release formulations.
The solubility study of the SSZ showed that the 
increase of pH caused an increase in the SSZ solubility. 
SSZ is a weak acid and presents partial ionization of the 
acid group. For weak acids when the pH of the medium 
FIGURE 6 - Dissolution profiles of suspensions of SSZ 
(250 mg/5 mL) mL in phosphate buffer saline pH 5.8 with 0.5% 
polysorbate 80, at rotations of 25 rpm (A) and 50 rpm (B). Mean 
and standard deviation of n=6 determinations.
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FIGURE 7 - Dissolution profiles of suspensions of SSZ 
(250 mg/5 mL) mL in phosphate buffer saline pH 6.8, at rotations 
of 25 rpm (A) and 50 rpm (B). Mean and standard deviation of 
n=6 determinations.
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FIGURE 8 - Dissolution profiles of the suspension of 
sulfasalazine 250 mg/5 mL in phosphate buffer saline pH 7.4, 
at rotations of 25 rpm (A) and 50 rpm (B). Mean and standard 
deviation of n=6 determinations.
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FIGURE 9. Dissolution profile of the Azulfin® tablets in 
phosphate buffer saline pH 7.4, at rotation of 100 rpm. Mean 
and standard deviation of n=6 determinations.
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increases, the solubility of the acid also increases due to the 
contribution of the ionized form (Horter; Dressman; 2001).
Sulfasalazine is a classic example of a prodrug. 
It undergoes cleavage of the diazo bond in the colon by 
the metabolic action of bacterial colonies, thus releasing 
5-aminosalicylic acid (5-ASA) and sulfapyridine. This 
release process occurs in biological environments with 
pH between 5.5 and 7, conditions that exist in the cecum, 
colon and rectum. It is important for SSZ to dissolve 
completely in these sites to enable its metabolism. 
Therefore, the profiles found here indicate that in the 
suspension formulations studied, the drug will be available 
in soluble form during its passage through the large 
intestine, enabling its delivery to the action sites (Sinko, 
2008; Santos Junior, 1999; Dahan, Amidon, 2010).
The result of the dissolution test of the Azulfin® 
tablet in gastric juice (HCl 0.1 N, pH 1.2) was satisfactory, 
because the percentage of dissolved drug was less than 
0.5%. For the first stage (acid medium), the percentage 
of drug dissolved should not exceed 10% (USP, 2011b). 
The results of the dissolution profile in PBS pH 7.4 
are exhibited in the Figure 9. For the second stage, 
the percentage of drug dissolved should exceed 90% 
according to USP(2011b). The result was excellent, 
because percentage of dissolved drug was 104 ± 2.1% 
at 90 minutes. However, the suspension showed SSZ 
dissolution percentage of 100% at 10 minutes in medium 
PBS pH 7.4 with at rotation of 50 rpm. Thus, the 
suspension exhibited faster dissolution rate than the tablet.
Due to the coating, the coated tablets exhibit 
slower dissolution than suspensions. The coating must 
be broken by aqueous dissolution medium to start the 
disintegration of the tablet core. Thus, the disintegration 
process promotes the drug dissolution. The suspensions 
are disperse systems and do not suffer disintegration. In 
this case, the drug particles in suspension suffer rapid 
dissolution after contact with the dissolution medium. 
The SSZ suspensions are liquid formulations that 
facilitate swallowing and exhibit fast dissolution in 
comparison with reference formulation (Azulfin® tablet). 
However, the suspensions have some disadvantages 
in comparison with solid formulations. Suspensions 
usually suffer sedimentation and must be homogenized 
by stirring before use. Moreover, suspensions can exhibit 
unpleasant taste, however, this problem can be corrected 
with sweeteners and flavoring. 
CONCLUSIONS
Control of the particle size is important because 
this parameter can cause differences in the physical and 
chemical characteristics, such as solubility, viscosity and 
homogeneity of suspensions. Differences of solubility 
between SSZ-D, SSZ-H and SSZ-P, obtained from the 
three suppliers, were found in the dissolution media. 
This shows the importance of quality control in the 
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supplier qualification. The suspension of sulfasalazine 
250 mg/5 mL is a formulation that is easy to prepare, both 
by compounding pharmacies and mass manufacturers. 
The dissolution study of the suspensions showed that the 
formulations presented very fast dissolution rates, with 
levels higher than 85% in 20 minutes in the phosphate 
buffer pH 5.8, phosphate buffer pH 5.8 with 0.5% 
polysorbate 80, phosphate buffer pH 6.8 and phosphate 
buffer pH 7.4 media, at a rotation speed of 50 rpm. The SSZ 
samples obtained from the three suppliers (D, H and P) 
presented similar dissolution profiles, since there were no 
significant differences between them (P>0.05) in the same 
four media at rotation of 50 rpm. The rotation speed of 
50 rpm is the most suitable for the dissolution studies of the 
suspensions. The sulfasalazine 250 mg/5 mL suspension 
dissolved rapidly and is a promising formulation for 
clinical use to treat chronic intestinal inflammatory 
diseases, especially for administration to newborns, young 
children and the elderly. The liquid formulation is more 
flexible regarding administration and dosage adjustment 
than the solid form.
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